Cochrane · systematic review · CD007667
Pharmacological interventions for antisocial personality disorder
Khalifa, NR, Gibbon, S, Völlm, BA, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
25
current version
GRADE rated
6
No studies
18
Included studies
NR
No studies 18 · 72%Ungraded 1 · 4%Very low 6 · 24%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Phenytoin (antiepileptic) versus placebo
Population: adults with antisocial personality disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aggression Measured by: frequency of aggressive acts Phenytoin (antiepileptic) vs placebo | no estimate extracted | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Reconviction Phenytoin (antiepileptic) vs placebo | no estimate extracted | NR | No studies |
Global state/functioning Phenytoin (antiepileptic) vs placebo | no estimate extracted | NR | No studies |
Social functioning Phenytoin (antiepileptic) vs placebo | no estimate extracted | NR | No studies |
Adverse events Measured by: number of participants reporting nausea during week 1 Phenytoin (antiepileptic) vs placebo | OR 1 [0.06, 16.76] | 1 study · 60 participants | Very low Downgraded: risk of bias, imprecision |
Desipramine (antidepressant) versus placebo
Population: adults with antisocial personality disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aggression Desipramine (antidepressant) vs placebo | no estimate extracted | NR | No studies |
Reconviction Desipramine (antidepressant) vs placebo | no estimate extracted | NR | No studies |
Global state/functioning Desipramine (antidepressant) vs placebo | no estimate extracted | NR | No studies |
Social functioning Measured by: the Family‐Social domain of ASI (scores range from 0 to 1, with higher values indicating worse social functioning) Desipramine (antidepressant) vs placebo | no estimate extracted | 1 study · 29 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Adverse events Desipramine (antidepressant) vs placebo | no estimate extracted | NR | No studies |
Nortriptyline (antidepressant) versus placebo
Population: men with alcohol dependency
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aggression Nortriptyline (antidepressant) vs placebo | no estimate extracted | NR | No studies |
Reconviction Nortriptyline (antidepressant) vs placebo | no estimate extracted | NR | No studies |
Global state/functioning Measured by: Global Assessment of Functioning Scale (scores range from 0‐100, with higher scores indicating better functioning) and the General Severity Index (GSI) subscale of the Symptom Check List‐90 (GSI), which uses m... Nortriptyline (antidepressant) vs placebo | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Social functioning Nortriptyline (antidepressant) vs placebo | no estimate extracted | NR | No studies |
Adverse events Nortriptyline (antidepressant) vs placebo | no estimate extracted | 20 participants | Ungraded |
Bromocriptine (dopamine agonist) versus placebo
Population: adults with antisocial personality disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aggression Bromocriptine (dopamine agonist) vs placebo | no estimate extracted | NR | No studies |
Reconviction Bromocriptine (dopamine agonist) vs placebo | no estimate extracted | NR | No studies |
Global state/functioning Measured by: General Severity Index (GSI) subscale of the Symptom Check List‐90 (GSI), which uses mean subscale scores (range from 0‐4, with higher scores indicating greater severity of symptoms) Bromocriptine (dopamine agonist) vs placebo | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision |
Social functioning Bromocriptine (dopamine agonist) vs placebo | no estimate extracted | NR | No studies |
Adverse events Measured by: self‐reported medication side effects Bromocriptine (dopamine agonist) vs placebo | no estimate extracted | 1 study · 18 participants | Very low Downgraded: risk of bias, imprecision |
Amantadine (dopamine agonist) versus placebo
Population: adults with antisocial personality disorder
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Aggression Amantadine (dopamine agonist) vs placebo | no estimate extracted | NR | No studies |
Reconviction Amantadine (dopamine agonist) vs placebo | no estimate extracted | NR | No studies |
Global state/functioning Amantadine (dopamine agonist) vs placebo | no estimate extracted | NR | No studies |
Social functioning Amantadine (dopamine agonist) vs placebo | no estimate extracted | NR | No studies |
Adverse events Amantadine (dopamine agonist) vs placebo | no estimate extracted | NR | No studies |